FIREFLY-1 trial of DAY101 in relapsed pLGG shows positive initial data

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The ongoing, open-label, single-arm, pivotal phase II FIREFLY-1 clinical trial, evaluating DAY101 (tovorafenib) as once-weekly monotherapy in patients aged 6 months to 25 years with relapsed or progressive pediatric low-grade glioma, yielded positive initial data from the first 22 patients enrolled. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Ronald McDonald House New York announced the completion of its renovation of the Community Floor, a reimagined space designed to enhance the everyday experience of children and families staying at the House while their children receive treatment for serious illnesses. The project, which has transformed dining, kitchen, play, and program areas on the second floor of the House at 405 East 73rd Street, creates spaces where families can share meals, children can play and learn, and caregivers can find opportunities for connection, respite, and support.
Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (1B, 2, and 3A) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent, according to the updated exploratory results from the ADAURA phase III trial. 
Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login